NeoImmuneTech, Inc.
A clinical-stage biopharma developing T cell-focused immuno-therapeutics for diseases.
950220 | KO
Overview
Corporate Details
- ISIN(s):
- KR8840140006
- LEI:
- Country:
- United States of America
- Address:
- 2400 Research Boulevard, Suite 250, Rockville, MD 20850, Rockville
- Website:
- https://www.neoimmunetech.com/en
Description
NeoImmuneTech, Inc. is a clinical-stage, T cell-focused biopharmaceutical company dedicated to the development of novel immuno-therapeutics. The company's lead asset is NT-I7 (efineptakin alfa), a long-acting human interleukin-7 (IL-7) fusion protein designed to amplify and reinvigorate T cells. This core technology aims to enhance the immune system's ability to eliminate cancer cells and pathogens. NT-I7 is being developed as a foundational immuno-oncology therapy for use in combination with other cancer treatments, such as checkpoint inhibitors, as well as for applications in infectious diseases. The company's research is focused on leveraging T cell amplification to address a wide range of challenging diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-07-12 00:00 |
투자판단관련주요경영사항(임상시험계획자진취하등)(NT-I7 (NIT-106 (고위험 피부암)) 임상 1b/2a상 시험 자진 중단)
|
Korean | 10.4 KB | ||
| 2023-07-12 00:00 |
투자판단관련주요경영사항(임상시험계획자진취하등)(NT-I7 (NIT-109 (위암)) 임상 2상 시험 자진 중단)
|
Korean | 11.5 KB | ||
| 2023-07-04 00:00 |
기업설명회(IR)개최
|
Korean | 6.7 KB | ||
| 2023-06-26 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 22.0 KB | ||
| 2023-06-08 00:00 |
주식등의대량보유상황보고서(약식)
|
Korean | 82.5 KB | ||
| 2023-05-15 00:00 |
분기보고서 (2023.03)
|
Korean | 1.1 MB | ||
| 2023-03-31 00:00 |
정기주주총회결과
|
Korean | 24.0 KB | ||
| 2023-03-31 00:00 |
사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | 8.4 KB | ||
| 2023-03-31 00:00 |
주식매수선택권부여에관한신고
|
Korean | 19.1 KB | ||
| 2023-03-23 00:00 |
감사보고서제출
|
Korean | 27.0 KB | ||
| 2023-03-23 00:00 |
사업보고서 (2022.12)
|
Korean | 1.4 MB | ||
| 2023-03-22 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.6 KB | ||
| 2023-03-16 00:00 |
주주총회소집공고
|
Korean | 179.9 KB | ||
| 2023-03-10 00:00 |
투자판단관련주요경영사항(NIT-116 (코로나바이러스감염증-19) 임상1상 자진중단)
|
Korean | 12.2 KB | ||
| 2023-03-09 00:00 |
주식등의대량보유상황보고서(약식)
|
Korean | 68.8 KB |
Automate Your Workflow. Get a real-time feed of all NeoImmuneTech, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for NeoImmuneTech, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for NeoImmuneTech, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
